Exclusive Summary

• EU-EMA GMP certified with BP/EP/USP compliant API, enabling fast-track registration and high-end market entry universally without extensive clinical hurdles.
• Although originator patents have expired, high manufacturing and raw material barriers for complex low-molecular-weight heparins limit generic saturation, providing a highly profitable market opportunity.
• Positioned as a first-line gold standard by global guidelines (ASCO/ESMO/ACCP) for cancer-associated thrombosis (CAT), addressing massive demand driven by roughly 10 million annual VTE cases worldwide.
• Backed by China's dominant position in the global heparin API supply chain, it offers highly competitive pricing, robust supply stability, and attractive profit margins for overseas distributors.